Abstract:Monitoring antibody prevalence is a valuable tool to evaluate the burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a community, identify risk factors, and assess the impact of clinical and public health intervention strategies. The antibody prevalence of SARS-CoV-2 in children in the United States in early 2022 was estimated by the Centers for Disease Control and Prevention to be 74.2%, using seroprevalence from a variety of sources. A study by the New Jersey Department of Health in late 2022/early 2023 in unvaccinated children found a lower prevalence, 68% when using a gum swab method to detect antibodies. This study compared the accuracy of the gum swab method to detect antibodies with simultaneously obtained serological samples in additional children. This cross-sectional study recruited well children, not vaccinated for SARS-CoV-2, aged 18 months to 11 years, who were scheduled for routine bloodwork at an inner-city university-based pediatric clinic. With parental consent, an extra 5 cc of blood and a gum swab sample were collected. Results from Diabetomics CovAb SARS-CoV-2 gum swab antibody test and Rutgers New Jersey Medical School enzyme-linked immunosorbent assay serology test for spike protein antibody were compared. The seropositivity of these paired samples was compared using McNemar's test, Cohen's kappa statistic, and other diagnostic accuracy statistics. From June through August 2023, 86 children were recruited. Antibody positivity by gum swab was 70.9% and by serology was 87.2%. The Cohen's kappa statistic was 0.39 indicating minimal agreement and McNemar's test was significant (P-value of 0.0010). Compared with serology, gum swab was 78.7% sensitive (95% CI 68.7% to 87.3%) and 81.8% specific (95% CI 48.2% to 97.7%). Positive and negative predictive values were 97.5% and 29.9%, respectively, and accuracy was 79.0%. Sensitivity in non-Hispanic versus Hispanic children was 74.2% versus 82.5%, and in children 6-11 years versus 18 months to 5 years, it was 74.2% versus 81.8%. While the gum swab method of antibody detection is not as sensitive or specific as serology, sample collection can be done in settings where phlebotomy is not feasible. This method could be useful in non-clinical settings such as surveillance, for assessing epidemiological trends and associations. Importance: Recently a study determining the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in unvaccinated children in NJ (Katic et al. 2023. Pediatric Academic Societies Meeting; Washington, D.C. https://2023.pas-meeting.org/searchbyposterbucket.asp?bm=Public+Health+%26+Prevention&t=Public+Health+%26+Prevention&pfp=Track) was conducted using a gum swab method for antibody detection. The Diabetomics CovAB test, which qualitatively identifies antibodies to SARS-CoV-2 spike protein, is a point-of-care, low-cost test, that is easy to administer in children. While this test provides sensitive and specific results in adults [US Food and Drug Administration (FDA). 2022. Center for devices and radiological health. EUA authorized serology test performance. Available from: https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance], data on its accuracy in children is lacking. As a follow-up to the above-mentioned study, we compared the results of the gum swab test to a serologic antibody test. We found that the gum swab test was inferior to serology but was fairly sensitive and specific with a high positive predictive value. While the test is not ideal for diagnostic purposes in children it can be a valuable tool for public health officials and pediatricians to understand the extent of past health interventions.

Evaluation of SARS-CoV-2 antibody response between paired fingerprick (hemaPEN) and venepuncture collected samples in children and adults

Unlocking the Potential of Dried Blood Spot Sampling for SARS-CoV-2 Antibody Detection: A Pathway to Efficient Pandemic Surveillance

Use of dried blood spot samples for SARS-CoV-2 antibody detection using the Roche Elecsys ® high throughput immunoassay

Validation of the Diabetomics CovAB SARS-CoV-2 antibody test in children: comparison with serology

A Dried Blood Spot protocol for high-throughput quantitative analysis of SARS-CoV-2 RBD serology based on the Roche Elecsys system

Quantitating SARS-CoV-2 neutralizing antibodies from human dried blood spots

Monitoring SARS-CoV-2 IgA, IgM and IgG antibodies in dried blood and saliva samples using antibody proximity extension assays (AbPEA)

Proteome profiling of home-sampled dried blood spots reveals proteins of SARS-CoV-2 infections

A Novel Dry-Stabilized Whole Blood Microsampling and Protein Extraction Method for Testing of SARS-CoV-2 Antibody Titers

Use of dried blood spots in the detection of coronavirus disease 2019 (COVID-19): A systematic review

Evaluation of commercial assays for the assessment of SARS-CoV-2 antibody response in hemodialysis patients

Performance of Dried Blood Spots Compared with Serum Samples for Measuring Dengue Seroprevalence in a Cohort of Children in Cebu, Philippines

Inter-laboratory harmonization of microsphere immunoassays for SARS-CoV-2 antibody detection in dried blood spots and oral fluids

Correlation of dried blood spots and plasma for quantification of Immunoglobulin (IgG) against Receptor binding domain and full length spike protein of SARS-CoV-2

A Highly Sensitive Immunoassay for Determination of Immune Response to SARS-CoV-2 in Capillary Blood Samples

Potential of a Bead-Based Multiplex Assay for SARS-CoV-2 Antibody Detection

Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Validation of Roche immunoassay for severe acute respiratory coronavirus 2 in South Africa

Variant-specific antibody profiling for tracking SARS-CoV-2 variant infections in children and adolescents

Point of care detection of SARS-CoV-2 antibodies and neutralisation capacity-lateral flow immunoassay evaluation compared to commercial assay to inform potential role in therapeutic and surveillance practices